EOG Resources Inc vs ResMed Inc. — how do they compare? EOG Resources Inc trades at $148.51 (market cap $77.90B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: EOG Resources Inc is far larger — about 2.4× ResMed Inc.'s market cap, and EOG Resources Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and ResMed Inc. for 51 Days on average.
| EOG | RMD | |
|---|---|---|
Market Cap | $77.90B | $31.89B |
Volume | 2,930,386 | 618,314 |
Sector | Energy | Health |
52-Week High | $153.74 | $277.88 |
52-Week Low | $101.78 | $182.82 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $81.24B | $31.24B |
Dividend Yield | 2.75% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, down 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $164.77 implying 14% upside. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations, while maintaining strong profitability with a 25.81% net income margin and 22.51% ROE. Recent news highlights operational strength and disciplined capital allocation, with upcoming Q3 2026 results scheduled for November 6, 2026.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E of 11.22, EV/EBITDA of 5.68) and strong shareholder returns through dividends. Key risks include oil price volatility, as seen in recent sector pullbacks, and execution of growth targets amid macroeconomic uncertainty. The absence of sell ratings from analysts and institutional accumulation support a positive medium-term outlook, though investors should monitor energy market dynamics and quarterly results.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →